West Pharmaceutical Services (WST) Projected to Release Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) will likely be announcing its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect West Pharmaceutical Services to announce earnings of $2.08 per share and revenue of $839.9790 million for the quarter. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.45. The company had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.West Pharmaceutical Services’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.45 earnings per share. On average, analysts expect West Pharmaceutical Services to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

West Pharmaceutical Services Trading Up 2.0%

WST opened at $359.32 on Wednesday. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. The stock’s fifty day moving average is $334.27 and its two-hundred day moving average is $286.00. The company has a market capitalization of $25.39 billion, a P/E ratio of 48.04, a PEG ratio of 2.85 and a beta of 1.16. West Pharmaceutical Services has a 52 week low of $211.10 and a 52 week high of $367.66.

Wall Street Analyst Weigh In

Several brokerages have recently commented on WST. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Evercore reaffirmed an “outperform” rating and issued a $410.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 6th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Finally, Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $310.00 to $400.00 in a research note on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, West Pharmaceutical Services currently has an average rating of “Buy” and an average price target of $363.17.

Insider Buying and Selling at West Pharmaceutical Services

In related news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. The trade was a 37.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On West Pharmaceutical Services

Several hedge funds have recently modified their holdings of WST. Generation Investment Management LLP boosted its stake in West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock worth $429,733,000 after purchasing an additional 585,855 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of West Pharmaceutical Services by 67.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock worth $323,280,000 after buying an additional 473,547 shares during the last quarter. Steadfast Capital Management LP acquired a new stake in shares of West Pharmaceutical Services during the third quarter worth $123,667,000. AQR Capital Management LLC grew its holdings in shares of West Pharmaceutical Services by 420.1% during the third quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock valued at $142,949,000 after buying an additional 440,929 shares during the last quarter. Finally, Viking Global Investors LP purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at $81,174,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.